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Toll-like receptorsMicrobial metabolites are known to affect immune system, brain, and behavior via activation of pattern
recognition receptors such as Toll-like receptor 4 (TLR4). Unlike the effect of the TLR4 agonist
lipopolysaccharide (LPS), the role of other TLR agonists in immune-brain communication is insufficiently
understood. We therefore hypothesized that the TLR2 agonist lipoteichoic acid (LTA) causes immune
activation in the periphery and brain, stimulates the hypothalamic-pituitary-adrenal (HPA) axis and
has an adverse effect on blood-brain barrier (BBB) and emotional behavior. Since LTA preparations
may be contaminated by LPS, an extract of LTA (LTAextract), purified LTA (LTApure), and pure LPS
(LPSultrapure) were compared with each other in their effects on molecular and behavioral parameters
3 h after intraperitoneal (i.p.) injection to male C57BL/6N mice.
The LTAextract (20 mg/kg) induced anxiety-related behavior in the open field test, enhanced the circu-
lating levels of particular cytokines and the cerebral expression of cytokine mRNA, and blunted the cere-
bral expression of tight junction protein mRNA. A dose of LPSultrapure matching the amount of endotoxin/
LPS contaminating the LTAextract reproduced several of the molecular and behavioral effects of LTAextract.
LTApure (20 mg/kg) increased plasma levels of tumor necrosis factor-a (TNF-a), interleukin-6 and
interferon-c, and enhanced the transcription of TNF-a, interleukin-1b and other cytokines in the amyg-
dala and prefrontal cortex. These neuroinflammatory effects of LTApure were associated with transcrip-
tional down-regulation of tight junction-associated proteins (claudin 5, occludin) in the brain. LTApure
also enhanced circulating corticosterone, but failed to alter locomotor and anxiety-related behavior in
the open field test.
These data disclose that TLR2 agonism by LTA causes peripheral immune activation and initiates neu-
roinflammatory processes in the brain that are associated with down-regulation of BBB components and
activation of the HPA axis, although emotional behavior (anxiety) is not affected. The results obtained
with an LTA preparation contaminated with LPS hint at a facilitatory interaction between TLR2 and
TLR4, the adverse impact of which on long-term neuroinflammation, disruption of the BBB and mental
health warrants further analysis.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
There is abundant evidence that bacterial infection of
peripheral tissues causes innate immune cells to produce pro-
inflammatory cytokines which act on the brain to cause sickness
as well as molecular and behavioral perturbations (Dantzer et al.,
2008). The immune system senses bacterial intrusion via pattern
recognition receptors (PRRs) which recognize evolutionarily highly
conserved structures on pathogens, so-called pathogen associated
molecular patterns (PAMPs). Toll-like receptors (TLRs) represent
the best characterized family of PRRs which are expressed on the
R. Mayerhofer et al. / Brain, Behavior, and Immunity 60 (2017) 174–187 175cell surface and thus can initiate a first-line immune response
against invading pathogens (Medzhitov et al., 1997). Toll-like
receptor 4 (TLR4), for instance, is responsible for the recognition
of lipopolysaccharide (LPS) on the cell wall of gram-negative bac-
teria (Poltorak et al., 1998). Upon binding of LPS to TLR4, which
requires the presence of myeloid differentiation 2, the signaling
cascade targets myeloid differentiation primary response protein
88 and results in the release of pro-inflammatory cytokines
(Kawai et al., 1999). If LPS is endocytosed, the TRIF-related adaptor
molecule/TIR-domain-containing adapter-inducing interferon-b
pathway is activated and causes release of type 1 interferons
(Kawai and Akira, 2010). Through these immune mediators, LPS
is known to cause sickness and evoke signs of anxiety- and
depression-like behavior in rodents (Bluthé et al., 1994; O’Connor
et al., 2009; Painsipp et al., 2010; Sulakhiya et al., 2016). In
humans, symptoms of depression and anxiety are correlated with
LPS exposure and subsequent cytokine release (Vogelzangs et al.,
2016), and increased IL-6 and INF-a levels correlate with severity
of depression and anxiety (Capuron et al., 2009; Raison et al.,
2006).
The family of TLRs comprises 12 members (10 in humans)
(Pandey et al., 2015) which are targeted by different PAMPs
(Kawai and Akira, 2010). Under conditions of bacterial invasion it
is likely that different PRRs are activated in parallel and that the
ensuing immune and brain responses are the result of the positive
and/or negative interactions between the PRR-mediated reactions.
For instance, the sickness response to LPS is enhanced by synergism
between TLR4 and the nuclear-binding domain (NOD)-like recep-
tors NOD1 and NOD2, which recognize peptidoglycan elements
(Farzi et al., 2015b). In contrast, lipoteichoic acid (LTA) is a major
cell wall component of gram-positive bacteria and a PAMP that is
primarily recognized by Toll-like receptor 2 (TLR2) (Hermann
et al., 2002). LTA is a surface-associated adhesion amphiphile com-
posed of a soluble polymer, consisting of polyhydroxy alkane units,
such as ribitol and glycerol, attached to the cell membrane with a
diacylglycerol. The sequence of glycerol and ribitol repeat units var-
ies between species (Schneewind and Missiakas, 2014). Bacterioly-
sis leads to the release of LTA into the bloodstream, which occurs in
response to b-lactam antibiotic treatment (Van Langevelde et al.,
1998). LTA induces the secretion of cytokines such as IL-1b and
TNF-a, which can contribute to the disruption of the blood-brain
barrier (BBB) (Boveri et al., 2006). In addition, LTA is required for
anchoring microorganisms to brain microvascular endothelial cells
that disrupt the BBB (Sheen et al., 2010).
Despite the deleterious impact mediated by LTA on BBB func-
tion, the effects of this PAMP on molecular changes in the
immune-brain axis and on behavior have not yet been explored.
As concerns regarding the contamination of commercial LTA
preparations by LPS have been raised (Gao et al., 2001; Morath,
2001), the present study was conducted with an extract (LTAextract)
and a purified preparation of LTA (LTApure). The effects of these LTA
preparations on the immune-brain axis were compared with the
effects of ultrapure LPS (LPSultrapure). The first specific aim was to
examine whether behavior in the open field, indicative of sickness
and/or anxiety, is affected by intraperitoneally (i.p.) injected LTA
from Bacillus subtilis. The second aim was to examine the effect
on immune activation in the periphery and brain as reflected by
the expression of cytokines in the plasma, amygdala and prefrontal
cortex. Given that the HPA axis is activated by extrinsic and intrin-
sic stressors (Borrow et al., 2016) including immune activation
(Farzi et al., 2015b; Lehmann et al., 2013), the third aim was to
assess the effect of LTA on circulating corticosterone. The fourth
aim was to evaluate the potentially deleterious effect of LTA on
BBB composition by studying the transcriptional regulation of tight
junction-associated proteins in the amygdala and prefrontal
cortex.2. Methods and materials
2.1. Experimental animals
The experiments were performed with 10-week-old male
C57BL/6N mice (n = 188; 22–27 g body weight) obtained from
Charles River (Sulzfeld, Germany). The animals were housed in
pairs in a vivarium under controlled conditions: temperature set
point at 22 C, air humidity set point at 50% and a 12 h light/dark
cycle. Tap water and standard laboratory chow were provided
ad libitum throughout the experiment.
2.2. Ethics statement
The experimental procedure and number of animals used were
approved by the ethical committee at the Federal Ministry of
Science, Research, and Economy of the Republic of Austria (BMW
F-66.010/0026-WF/II/3b/2014) and conducted according to the
Directive of the European Parliament and of the Council of Septem-
ber 22, 2010 (2010/63/EU). The experiments were designed in such
a way that both the number of animals used and their suffering
was minimized.
2.3. Reagents
LTA from Bacillus subtilis was obtained from two different ven-
dors (Sigma-Aldrich, Vienna, Austria, catalog number L3265, from
here on referred to as LTAextract, and Invivogen, Toulouse, France,
catalog number tlrl-lta, from here on referred to as LTApure). LPS
from Escherichia coli O111:B4 extracted by successive enzymatic
hydrolysis steps and purified by the phenol-TEA-DOC extraction
protocol (LPSultrapure) was obtained from Invivogen (catalog num-
ber tlrl-3pelps). For TLR4 antagonism experiments, the TLR4 antag-
onist TAK-242 was used (Calbiochem/Merck Millipore, Darmstadt,
Germany; catalog number US1614316, resatorvid, ethyl (6R)-6-[N-
(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate)
(Ii et al., 2006; Kawamoto et al., 2008).
2.4. Activation of TLR2 and TLR4 in the HEK-Blue reporter cell assay
HEK-Blue (Invivogen, Toulouse, France) hTLR2 and hTLR4
cells were grown in Dulbecco’s Modified Eagle Medium (Gibco,
ThermoFisher, Waltham, MA, USA) containing 4.5 g/l glucose, 2 nM
L-glutamine, 10% fetal bovine serum, 1% penicillin-streptomycin
and 1 x HEK-Blue Selection at 37 C and 5% CO2. After confluency
was reached, cells were seeded into 24-well plates, 2.5  105 cells/
well. Cells were then treated with 102 pg/ml, 104 pg/ml, or 106
pg/ml of LTApure, LTAextract, or LPSultrapure and incubated for 24 h.
Sterile, distilled H2O was used as control.
To assess the TLR4 specificity of the agonists, cells were incu-
bated overnight (12 h) with 3 lM TAK-242 dissolved in DMSO.
DMSO was used as control at a concentration that did not exceed
0.2%. Following the overnight treatment with TAK-242 or DMSO,
LTAextract (106 pg/ml) or LPSultrapure (104 pg/ml, or 106 pg/ml) was
added, after which the cells were incubated for 24 h.
For quantitation of TLR2 and TLR4 activation, 180 ll of
HEK-Blue Detection medium was added to a 96-well plate, and
20 ll of supernatant from the treated cells was added. Alkaline
phosphatase activity was subsequently measured with a Victor
plate reader (PerkinElmer, Rodgau, Germany) at 655 nm.
2.5. Quantitation of endotoxin in LTAextract with the EndoLISA

endotoxin detection assay
To determine the amount of endotoxin present in LTAextract, the
EndoLISA (Hyglos, Bernried am Starnberger See, Germany)
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500 EU/ml was used. The assay was performed according to the
manufacturer’s instructions.
2.6. Experimental groups and timelines of the in vivo experiments
The animals were given two weeks to get accustomed to the
vivarium at the institute before any experiments were performed.
To reduce extrinsic stressors affecting the experiments, they were
transferred to the behavioral test room at least 16 h (overnight)
before behavioral testing or euthanization.
Preliminary experiments involving 7 groups (n = 6–8 per group)
of mice were conducted to study the effect of LTAextract in the open
field test with regard to dosage and timeline. Initially LTAextract
(0.15 mg and 0.5 mg per mouse) or its vehicle (pyrogen-free sterile
saline, 8 ml/kg) was administered i.p. 3 h before the open field test
was performed. Next, 0.5 mg LTAextract (corresponding to 20 mg/kg
in a 25 g mouse) or its vehicle was administered i.p. to test for any
behavioral effect in the open field test 6 h and 27 h post-injection.
All further experiments were conducted with the 20 mg/kg LTA
dose injected i.p. 3 h prior to behavioral testing or organ collection.
To compare the effects of LTApure, LTAextract, and LPSultrapure, rel-
ative to their vehicle, on behavior in the open field, six groups
(n = 6–8 per group) of mice were employed. For the collection of
blood and brains, six additional groups (n = 5–9 per group) treated
with LTApure, LTAextract, LPSultrapure or their vehicle were used to
exclude any potential confounding effects of behavioral tests on
molecular marker expression. All three TLR agonists were dis-
solved in pyrogen-free sterile saline right before administration
and injected i.p. LTApure and LTAextract were administered at a dose
of 20 mg/kg and a volume of 5 ml/kg, while LPSultrapure was given at
a dose of 1938 EU/kg and a volume of 7.75 ml/kg, corresponding to
the amount of 97 EU/mg endotoxin detected in the 20 mg/kg
LTAextract dose by means of the EndoLISA endotoxin quantification
assay. The vendor of LPSultrapure does not provide any information
on the EU/weight ratio of this preparation. According to a formula
given by the vendor of the EndoLISA assay (1 EU  100 pg E. coli
LPS; www.hyglos.de) the dose of 1938 EU/kg LPSultrapure would
roughly correspond to 0.19 mg/kg. This quantity appears plausible,
as a dose of 0.1 mg/kg LPS has previously been found to affect
behavioral parameters in the LabMaster system (Farzi et al.,
2015a,b). As control treatment, pyrogen-free sterile saline was
used at a volume of 5 ml/kg. Due to the experimental schedule a
maximum of 16 animals could be used per day. Therefore the
experiments were performed in a consecutive manner, each treat-
ment group (LTApure, LTAextract, LPSultrapure) being compared with a
separate vehicle group, which is also reflected in the statistical
analysis (independent samples t test). Injections were made
between 9:00 am and 12:00 pm, and the open field test and the
plasma/organ collections were performed 3 h after the injection
of the respective TLR agonist or its vehicle.
For the in vivo assessment of the effects of TAK-242 on corticos-
terone levels, six additional groups (n = 7–8 per group) of animals
were used. The animals received 4 mg/kg of TAK-242 dissolved in
11% DMSO i.p. at a volume of 10 ml/kg, and 30 min later the
animals received either 20 mg/kg LTApure or LTAextract as well via
i.p. injection. As control treatments, either 11% DMSO (vehicle for
TAK-242) or pyrogen-free sterile saline (vehicle for LTApure or
LTAextract) were used, respectively (Farzi et al., 2015a). Blood was
collected 3 h after the injection of LTApure or LTAextract.
2.7. Open field test
The open field consisted of an opaque grey box
(50  50  30 cm, B W  H), illuminated by 35 lx at floor level.
The central area (CA) was defined as 36  36 cm square in themiddle, leaving a 7 cm boarder zone on each side. The test was per-
formed individually on each mouse. The animals were placed in
the center of the box, and their behavior (time in CA, CA visits,
and total traveling distance) was tracked for 5 min by a video
camera mounted above the open field and recorded with the
VideoMot2 (TSE Systems, Bad Homburg, Germany) software.
2.8. Blood sampling and collection of brains
Animals were deeply anesthetized with pentobarbital (150 mg/
kg i.p.), and blood was collected via cardiac puncture. One hundred
ll of 3.8% sodium citrate was used as anticoagulant in each single-
use syringe. The samples were centrifuged at 7000 rpm and 4 C for
15 min, then plasma was collected and stored at 70 C until fur-
ther processing. After blood collection, brains were collected and
immediately frozen for 5 s in 2-methylbutane on dry ice. Brains
were wrapped in aluminum foil and stored at 70 C.
2.9. Circulating corticosterone
Corticosterone levels in plasma were determined via an
enzyme-linked immunosorbent assay (Assay Designs, Ann Arbor,
Michigan, USA). The manufacturer’s specifications state a sensitiv-
ity of 27.0 pg/ml and intra- and inter-assay coefficients of variation
of 7.7% and 9.7%, respectively. The assay was performed according
to the manufacturer’s instructions.
2.10. Circulating cytokines in plasma
To determine levels of IL-1b (catalog number EPX01A-26002),
IL-6 (EPX01A-20603), IL-10 (EPX01A-20614), INF-c (EPX01A-
20606), and TNF-a (EPX01A-20607), the magnetic bead-based Pro-
cartaPlexTM immunoassay (catalog number EPX010-20440-901,
eBioscience, San Diego, CA, USA) was used. The fluorescent signal
was quantified with the Bio-Plex 200 multiplex suspension array
system equipped with Luminex xMAP technology and the
Bio-Plex 5.0 software (BioRad, Hercules, CA, USA). The assay was
performed according to the manufacturer’s instructions.
2.11. Microdissection of amygdala and prefrontal cortex
The brains were microdissected by a trained researcher on a
cold plate (Weinkauf Medizintechnik, Forchheim, Germany) at
20 C (Brunner et al., 2014). The instruments were cleaned with
RNase AWAY (Carl Roth, Karlsruhe, Germany) before and in
between uses. The prefrontal cortex (Bregma +3.20 to 0.22) and
amygdala (Bregma 0.58 to 2.54) were microdissected under a
stereomicroscope. The dissected brain samples were transferred
to micro packaging tubes with Precellys beads (Peqlab, Erlangen,
Germany) and stored at 70 C until further processing.
2.12. Reverse transcriptase polymerase chain reaction (RT-PCR) and
quantitative real-time PCR (qPCR) of amygdala and prefrontal cortex
Amygdala and prefrontal cortex sections were homogenized
with the Precellys 24 homogenizer (Peqlab, Erlangen, Germany).
Subsequently, RNA was extracted according to the manufacturer’s
instructions using the RNeasy lipid tissue mini kit (Qiagen, Hilden,
Germany). The RNA concentration in each sample was determined
via NanoDrop (Thermo Scientific, DE, USA). Afterwards, 2 lg of
RNA was reverse-transcribed with the high capacity cDNA reverse
transcription kit (Fisher Scientific, Vienna, Austria) according to
the manufacturer’s instructions, using the Mastercycler Gradient
(Eppendorf, Hamburg, Germany). Relative quantitation of mRNA
levelswas performed via qPCRusing a LightCycler 480 systemwith
TaqMan gene expression assays for CLDN5 (catalog number
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93699_m1), CCL2 (Mm00441242_m1), IL-1b (Mm00434228_m1),
IL-6 (Mm00446190_m1), IL-10 (Mm01288386_m1), INF-c
(Mm01168134_m1), and TNF-a (Mm00443258_m1), and a master
mix (catalog number 4369510, Fisher Scientific, Vienna, Austria).
Controls without reverse transcriptase were included for each brain
area and treatment group. ACTB (Mm00607939_s1), GAPDH
(Mm99999915_g1), and PPIL3 (Mm00510343_m1) were used as
endogenous reference genes. The 2DDCt method was used to quan-
titate target gene levels relative to controls. Differences in treatment
groups were expressed as fold changes.
2.13. Statistics
Results were statistically analyzed using GraphPad Prism5
(GraphPad Software Inc., La Jolla, CA, USA) or SPSS 22 (SPSS Inc.,
Chicago, IL, USA). Homogeneity of variances was assessed with
the Kolmogorov-Smirnov test. Differences between groups were
analyzed with the unpaired samples t test. In case a non-
parametric test was required, the Mann–Whitney U test or Kruskal
Wallis test was used. Due to the consecutive setup of the experi-
ments, ANOVA was not permitted. Probability values of p 6 0.05
were regarded as statistically significant.3. Results
3.1. LTApure activates TLR2 but not TLR4 in the HEK-Blue
 reporter cell
assay, while LTAextract activates TLR4, but fails to activate TLR2
Given the concerns regarding the contamination of commercial
LTA by LPS (Gao et al., 2001; Morath, 2001), the HEK-Blue repor-
ter cell assay was used to investigate the TLR2/TLR4 specificity of
the three TLR agonists under study, LTAextract, LTApure, and
LPSultrapure.
Initial validation of the TLR4 system was performed with
LPSultrapure. As expected, LPSultrapure dose-dependently increased
secretion of alkaline phosphatase, and this effect was inhibited in
the presence of the TLR4 inhibitor TAK-242 (Fig. 1A). LTApure
dose-dependently activated TLR2-dependent secretion of alkaline
phosphatase, whereas LPSultrapure had no effect (Fig. 1B). In the
TLR4 reporter HEK-Blue cell line, LTApure was without effect
(Fig. 1C). LTAextract did not elicit TLR2 signaling (Fig. 1D), but acti-
vated TLR4 signaling in a concentration-dependent manner, this
effect being reduced to baseline in the presence of TAK-242
(Fig. 1E).
3.2. Lipopolysaccharide, but not pure lipoteichoic acid, induces
anxiety-like behavior in the open field test
The open field test was used to assess anxiety-like behavior in
response to systemic application of the TLR agonists under study.
The time spent in the CA, and the CA visits were used as a measure
of anxiety. More time spent in and more visits to the CA indicated
less anxiety. The locomotor activity deduced from the total
traveling distance was used as a measure of sickness. Preliminary
experiments (Table 1) showed that LTAextract at a dose of 0.5 mg/
mouse, but not 0.15 mg/mouse, enhanced anxiety-like behavior
as reflected by a significant diminution of the time spent in the
CA and the number of CA visits. This effect of LTAextract at 0.5 mg
per mouse (corresponding to 20 mg/kg in a 25 g mouse) was
observed 3 h, but not 6 h or 27 h, post-administration (Table 1).
Next we compared the effects of LTAextract, LTApure, and
LPSultrapure on the behavior in the open field test. LTApure had no sig-
nificant effect on any of the three parameters measured (Fig. 2A).
In line with the data shown in Table 1, LTAextract clearly tendedto reduce the time in the CA although the effect did not reach sta-
tistical significance (p = 0.0941) in this set of experiments. CA visits
and total traveling distance remained largely unaffected by
LTAextract (Fig. 2B). Systemic administration of LPSultrapure signifi-
cantly reduced the time in the CA (p = 0.0106, Fig. 2C), but had
no significant effect on CA visits or traveling distance. These results
indicate that LPSultrapure is anxiogenic, while LTApure has no effect
on anxiety-like behavior. LTAextract induced a behavioral pattern
more similar to LPSultrapure than LTApure.
3.3. LTApure, LTAextract, and LPSultrapure increase circulating
corticosterone
Given that LPS increases circulating corticosterone (Farzi et al.,
2015b), the plasma concentration of this glucocorticoid was mea-
sured to quantify the effects of LTApure and LTAextract, relative to
LPSultrapure, on HPA axis activity. As is shown in Fig. 3A, LTApure,
LTAextract, and LPSultrapure all significantly increased plasma corti-
costerone compared to the respective vehicle.
3.4. The TLR4 antagonist TAK-242 attenuates the increase in plasma
corticosterone levels induced by LTAextract but not LTApure
To investigate the effects of LTApure and LTAextract on TLR4 sig-
naling in vivo, TAK-242 was administered i.p. 30 min before admin-
istering LTApure or LTAextract. The basal levels of circulating
corticosterone were slightly, but significantly, elevated by TAK-
242 in comparison to the vehicle control (Fig. 3B). The effect of
LTApure to increase plasma corticosterone remained unaffected by
TAK-242 (Fig. 3B). In contrast, the effect of LTAextract to raise plasma
corticosterone was significantly blunted by TAK-242 (Fig. 3B).
3.5. LTApure, LTAextract, and LPSultrapure increase circulating cytokines
Circulating cytokines were determined to gauge the effect of
LTApure, LTAextract, and LPSultrapure on peripheral immune activation.
IL-6, INF-c, and TNF-a were significantly increased 3 h after treat-
ment with the TLR agonists compared to the respective vehicles
(Fig. 4B, D, E). The plasma concentrations of IL-1b and IL-10 in mice
treated with LTApure and LPSultrapure or the respective controls were
below the detection limit (Fig. 4A, C). In contrast, LTAextract signifi-
cantly increased IL-1b and IL-10 concentrations, relative to vehicle
(Fig. 4A, C).
3.6. LTApure, LTAextract, and LPSultrapure differentially affect transcription
of cytokines and tight junction-associated proteins in the amygdala
and prefrontal cortex
Amygdala and prefrontal cortex were chosen as test brain
regions based on their important role in anxiety (Maroun, 2013;
Robinson et al., 2016). Furthermore, anxiety is known to be influ-
enced by cytokines (Vogelzangs et al., 2016). LTApure induced a sig-
nificant increase in the expression of IL-1b, TNFa, and CCL2 mRNA
in the amygdala and prefrontal cortex, as well as of IL-6 mRNA in
the prefrontal cortex (Fig. 5A, E, F and 5A, B, E, F). In contrast to
LTApure, LTAextract stimulated cytokine mRNA expression in addi-
tional brain regions and/or to a larger extent (Figs. 5 and 6).
LTAextract significantly enhanced the expression of IL-1b, IL-6, TNFa,
and CCL2 mRNA in the amygdala and prefrontal cortex, and of IL-
10 in the prefrontal cortex (Figs. 5A, B, E, F and 6A, B, C, E, F). The
effect of LTAextract to raise IL-6 and CCL2 mRNA expression in the
amygdala (Fig. 5B, F) and IL-6, IL-10, TNFa, and CCL2mRNA expres-
sion in the prefrontal cortex (Fig. 6B, C, E, F) was more pronounced
than that of LTApure. LPSultrapure significantly increased IL-1b, TNFa,
and CCL2 mRNA expression in the amygdala and prefrontal cortex,
Fig. 1. Effect of LTApure, LTAextract, and LPSultrapure on alkaline phosphatase release in HEK-Blue TLR2 and TLR4 reporter cells. HEK-Blue TLR4 (A, C, E) and TLR2 (B, D) cells
were incubated with LPSultrapure (102 pg/ml, 104 pg/ml, 106 pg/ml; A), LTApure (102 pg/ml, 104 pg/ml, 106 pg/ml; B, C), or LTAextract (102 pg/ml, 104 pg/ml, 106 pg/ml; D, E). After
a 24 h incubation, alkaline phosphatase activity was determined at 655 nm on a plate reader. TAK-242 (TAK; 3 lM) was added to the cell suspensions 12 h prior to incubation
with LTAextract or LPSultrapure. The bars represent means + SD from one representative experiment performed in triplicates. *p 6 0.05, **p 6 0.01, ***p 6 0.001 compared to
vehicle (VEH)-treated cells; #p 6 0.05 compared to 106 pg/ml LPSultrapure; ##p 6 0.01 compared to 106 pg/ml LTAextract. The data in panels A, B, E were analyzed with the
independent samples t test, those in panels C, D with the non-parametric Kruskal-Wallis test.
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Table 1
Dose- and time-dependent effect of LTAextract on anxiety-like behavior in the open field test. The open field test was performed 3, 6 or 27 h after i.p. treatment of mice with
LTAextract at the dose/mouse indicated or its vehicle (VEH). The readouts represent means, n = 6–8; *p 6 0.05 compared to VEH-treated mice, independent samples t test.
Treatment VEH LTAextract LTAextract VEH LTAextract VEH LTAextract
Dose injected [mg] 0.15 0.5 0.5 0.5
Time of open field test post injection [h] 3 6 27
Time in central area [min] 1.32 0.88 0.63⁄ 0.98 1.08 0.85 1.06
Central area visits 28.83 24.05 16.88⁄ 17.57 20.71 20.17 22.43
Total traveling distance [m] 2.25 2.05 1.92 2.08 2.03 2.29 2.04
Fig. 2. Effect of LTApure, LTAextract, and LPSultrapure on anxiety-like behavior in the open field test. The graphs depict the time spent in the central area (CA), the number of CA
visits, and the total traveling distance during a 5 min test period. The open field test was performed 3 h after i.p. treatment with LTApure (20 mg/kg; A), LTAextract (20 mg/kg; B),
LPSultrapure (1938 EU/kg  0.19 mg/kg; C) or the respective vehicle (VEH). The bars represent means + SEM, n = 8–10; *p 6 0.05 compared to VEH-treated mice, independent
samples t test.
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6A, E, F).
To evaluate the impact of the TLR agonists on gene products
governing blood-brain-barrier composition, the mRNA expression
of tight junction-associated CLDN5, OCLN, and TJP1 was quanti-tated by qPCR. CLDN5 mRNA expression in the amygdala and pre-
frontal cortex was significantly decreased by LTApure and LTAextract,
while LPSultrapure significantly increased CLDN5 mRNA in both
amygdala and prefrontal cortex (Fig. 7A, B). OCLN mRNA expres-
sion in the amygdala was decreased by all three TLR agonists under
Fig. 3. Effect of LTApure, LTAextract, and LPSultrapure on plasma corticosterone levels.
Panel A depicts circulating corticosterone levels measured 3 h after i.p. treatment
with LTApure (20 mg/kg), LTAextract (20 mg/kg), LPSultrapure (1938 EU/kg  0.19 mg/
kg) or the respective vehicle (VEH). Panel B depicts circulating corticosterone levels
measured 3 h after i.p. treatment with LTApure (20 mg/kg) or LTAextract (20 mg/kg),
TAK-242 (TAK; 4 mg/kg) or its VEH being administered 30 min before LTApure or
LTAextract was given. The bars represent means + SEM, n = 6–8; *p 6 0.05,
***p 6 0.001 compared to VEH-treated mice, independent samples t test.
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was decreased by LTAextract and LPSultrapure, but not by LTApure
(Fig. 7D). TJP1 mRNA expression in the amygdala was slightly
decreased by LTApure and LTAextract, whereas TJP1 mRNA in the pre-
frontal cortex remained unaffected (Fig. 7E, F).4. Discussion
The current data reveal several important advances relating to
the communication between the peripheral immune system and
brain: (1) TLR2 agonism by purified LTA (LTApure) from Bacillus sub-
tilis causes immune activation in the periphery and brain as
reflected by a rise of distinct cytokines in plasma and increased
cytokine expression in the amygdala and prefrontal cortex. (2)
These immunologic changes are accompanied by a potentially
deleterious effect of LTA on BBB composition as mirrored by a
decrease in the expression of tight junction-associated proteins
in the brain. (3) Another effect of LTA-induced TLR2 stimulation
manifests itself in a rise of circulating corticosterone, indicative
of activation of the HPA axis. (4) These molecular responses to
TLR2 agonism do not extend to behavioral alterations related to
sickness and anxiety, as has been reported in response to stimula-tion of other PRRs such as TLR4, at least not at the LTA doses stud-
ied here. (5) The analysis of the biologic effects of LTA preparations
with submaximal purity can substantially be confounded by con-
taminations with endotoxin/LPS. (6) A comparison of the immuno-
logic and cerebral effects of an LTA extract with those of purified
LTA and LPS hints at a facilitatory interaction of the TLR2 and
TLR4 agonists present in the LTAextract, which may be of transla-
tional relevance to the consequences of bacterial translocation
and infection.
4.1. Dosage and purity of LTA
Previous work has shown that the TLR2 agonist LTA (purity not
specified) causes activation of peripheral as well as cerebral micro-
glial immune cells (Huang et al., 2013; Lim et al., 2013; Neher and
Brown, 2007; Oberg et al., 2011) and triggers the release of pro-
inflammatory cytokines (Medzhitov and Janeway, 1998). These
effects were confirmed by the present in vivo study in which the
plasma concentrations of IL-6, INF-c, and TNF-a were significantly
enhanced 3 h after i.p. administration of LTApure and LTAextract. The
dose of 20 mg/kg LTA and the measurement time points used here
were chosen in view of the preliminary results summarized in
Table 1. In this setting, LTAextract shortened the time spent in the
CA of the open field 3 h, but not 6 and 27 h post-treatment. In addi-
tion, analysis of the effects of the TLR4 agonist LPS has shown that
cytokine production and sickness behavior are maximal between 1
and 6 h post-injection (Dantzer et al., 2008; Layé et al., 1994). A
minimum of 3 h between treatment administration and analysis
was deemed necessary to exclude confounding effects of the stress
of handling and injection.
Stimulation of murine PRRs such as TLR4 by LPS has previously
been found to activate the HPA axis and cause the release of corti-
costerone (Farzi et al., 2015b; Lehmann et al., 2013). The present
study showed that LTA likewise enhances the plasma concentra-
tions of corticosterone, an effect that is triggered both by LTAextract
and LTApure. In view of the concerns regarding the contamination of
commercial LTA preparations by LPS (Gao et al., 2001; Morath,
2001) the involvement of TLR4 in the effect of LTA on HPA axis
activity was probed with the TLR4 antagonist TAK-242 (Ii et al.,
2006; Kawamoto et al., 2008). At the dose of 4 mg/kg (Farzi
et al., 2015a; Wang et al., 2013) TAK-242 blunted the rise of plasma
corticosterone induced by LTAextract, but not that by LTApure, which
indicates that the effect of LTAextract is largely due to contamination
by a TLR4 agonist, most likely LPS. This lack of specificity of
LTAextract for TLR2 was confirmed in TLR2/TLR4 HEK-Blue reporter
assays in which LTAextract, like LPSultrapure, stimulated TLR4,
whereas LTApure activated TLR2, but not TLR4. Corroborating these
pharmacologic properties, TAK-242 at the concentration of 3 lM
(concentration indicated in product leaflet by Invivogen) pre-
vented stimulation of TLR4 by LTAextract and LPSultrapure. In view
of the observations that, unlike LTApure, LTAextract displayed agonist
activity at TLR4, the immunologic, cerebral and behavioral effects
of these two LTA preparations were strictly analyzed in parallel
with those of LPSultrapure at a dose matching the amount of contam-
inating LPS present in LTAextract.
Currently we have no conclusive explanation why LTAextract,
unlike LTApure, failed to stimulate TLR2 in the HEK-Blue reporter
assay (Fig. 1A) although at the same time it was able to stimulate
TLR4 (Fig. 1B). We speculate that the interaction of LTA with
TLR2 in HEK-Blue cells is negatively regulated by unknown com-
ponents of the LTAextract and/or peculiarities in cellular transduc-
tion mechanisms, given that LTA signaling is determined by
many factors other than TLR2. Thus, the TLR2-mediated activation
of immune cells by LTA is enhanced by lipopolysaccharide-binding
protein and CD-14 but is independent of TLR4 and the co-receptor
MD-2 (Schröder et al., 2003). In order to activate the TLR2 signaling
Fig. 4. Effect of LTApure, LTAextract, and LPSultrapure on plasma cytokine levels. The graphs depict circulating levels of interleukin-1b (IL-1b; A), interleukin-6 (IL-6; B),
interleukin-10 (IL-10; C), interferon-c (INF-c; D), and tumor necrosis factor-a (TNF-a; E). LTApure (20 mg/kg), LTAextract (20 mg/kg), LPSultrapure (1938 EU/kg  0.19 mg/kg) or
the respective vehicle (VEH) was administered 3 h before the cytokines were assayed. The symbol <OOR refers to values below the detection limit. The bars represent means
+ SEM, n = 6–9; *p 6 0.05, **p 6 0.01, ***p 6 0.001 compared to VEH-treated mice, independent samples t test.
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although it has been argued that TLR2 is not necessary for LTA-
induced secretion of IL-8 after TLR2 is blocked with a TLR2 anti-
body (Hattar et al., 2006). In view of these circumstances, the fail-
ure of LTAextract to stimulate TLR2 in the reporter assay may be due
to (1) an inappropriate conformation of LTA to activate TLR2 and its
signaling cascade, (2) the presence of unknown components in the
LTAextract that interfere with TLR2 activation and transduction, and/
or (3) a negative regulation of TLR2 signaling by excess LPS in the
in vitro system. The presence of appreciable amounts of endotoxin/
LPS in the LTAextract, as shown by the HEK-Blue reporter cell assay,
is affirmed by the ability of the selective TLR4 inhibitor TAK-242 (Ii
et al., 2006; Kawamoto et al., 2008) to suppress the activity of the
LTAextract (Fig. 1E).4.2. Effect of LTA on circulating and cerebral cytokines as well as BBB
proteins
Purified and undamaged LTA from S. aureus has been reported
to stimulate the release of pro-inflammatory cytokines such as
TNF-a, INF-c, CCL2 (Kang et al., 2012), and interleukins 1, 5, 6,
and 8 from immune cells (Ginsburg, 2002). This was corroborated
in the current study where plasma IL-6, INF-c, and TNF-awere sig-
nificantly enhanced by LTApure, LTAextract, and LPSultrapure. The effect
of LPS on circulating cytokine levels is in line with another report
in which low doses of LPS (0.1 mg/kg) have been found to elevate
plasma levels of IL-1b and IL-6 (Farzi et al., 2015b). In the current
study it is particularly worth noting that the production of IL-1b
and anti-inflammatory IL-10 was stimulated by LTAextract only
Fig. 5. Effect of LTApure, LTAextract, and LPSultrapure on cytokine mRNA expression in the amygdala. The graphs depict the expression of interleukin-1b (IL-1b; A), interleukin-6
(IL-6; B), interleukin-10 (IL-10; C), interferon-c (INF-c; D), tumor necrosis factor-a (TNF-a; E), and chemokine (C-C motif) ligand 2 (CCL2; F) mRNA. LTApure (20 mg/kg),
LTAextract (20 mg/kg), LPSultrapure (1938 EU/kg  0.19 mg/kg) or the respective vehicle (VEH) was administered 3 h before the cytokines were assayed. mRNA transcription is
expressed as fold change relative to VEH-treated mice. The bars represent means + SEM, n = 5–7; *p 6 0.05, **p 6 0.01, ***p 6 0.001 compared to VEH-treated mice,
independent samples t test.
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higher after treatment with LTAextract than after treatment with
either LTApure or LPSultrapure. These observations are suggestive of
a facilitatory interaction between LTA, LPS and possibly other
PAMPs present in LTAextract. Synergies between activation of TLR4
by LPS and stimulation of TLR2 by diverse agonists have previously
been noted in various cellular systems (Beutler et al., 2001; Xu
et al., 2007).
The LTA-evoked peripheral immune activation extends to the
central nervous system in which the transcription of both cytoki-
nes and tight junction-associated proteins was significantly
altered. The molecular analysis focused on mRNA quantitation,
because this parameter provides a better reflection of the dynamicsof intervention-induced gene expression. LTApure increased the
expression of IL-1b, TNFa, and CCL2 mRNA in the amygdala and
prefrontal cortex and that of IL-6 mRNA in the prefrontal cortex.
These findings indicate that systemic administration of LTA
induces neuroinflammation in two brain areas (amygdala and pre-
frontal cortex) that are relevant to emotional-affective behavior
such as anxiety (Maroun, 2013; Robinson et al., 2016). Since
LTApure, LTAextract and LPSultrapure all increased peripheral circulat-
ing TNF-a levels, it is conceivable that this cytokine is one of the
master regulators transferring inflammation from the periphery
to the brain. This conclusion is supported by the finding that mice
lacking TNF receptors (TNFR1/2/) do not develop neuroinflam-
mation (Qin et al., 2007). Thus, systemic administration of LPS or
Fig. 6. Effect of LTApure, LTAextract, and LPSultrapure on cytokine mRNA expression in the prefrontal cortex. The graphs depict the expression of interleukin-1b (IL-1b; A),
interleukin-6 (IL-6; B), interleukin-10 (IL-10; C), interferon-c (INF-c; D), tumor necrosis factor-a (TNF-a; E), and chemokine (C-C motif) ligand 2 (CCL2; F) mRNA. LTApure
(20 mg/kg), LTAextract (20 mg/kg), LPSultrapure (1938 EU/kg  0.19 mg/kg) or the respective vehicle (VEH) was administered 3 h before the cytokines were assayed. The symbol
<OOR refers to values below the detection limit. mRNA transcription is expressed as fold change relative to VEH-treated mice. The bars represent means + SEM, n = 5–7;
*p 6 0.05, **p 6 0.01, ***p 6 0.001 compared to VEH-treated mice, independent samples t test.
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the brain of TNFR1/2/ mice (Qin et al., 2007). As LTApure,
LTAextract and LPSultrapure all elevated the circulating level of IL-6,
and LTAextract and LPSultrapure also enhanced its expression in the
amygdala, IL-6 may be another cytokine that significantly con-
tributes to immune signaling between periphery and brain. This
contention is in keeping with the emerging evidence that IL-6 plays
an important role in neuroinflammation and associated mental
disturbances (Burton et al., 2013; Qian et al., 2014; Spooren
et al., 2011). The observation that, relative to LTApure or LPSultrapure,
LTAextract stimulated cytokine mRNA expression in additional brain
regions and/or to a larger extent suggests that neuroinflammatory
processes in the brain may be facilitated by concomitant activation
of TLR2 and TLR4, although to a lesser extent than in the periphery.Peripheral as well as cerebral immune activation by both
LTAextract and LTApure went in parallel with a decreased transcrip-
tion of the tight junction-associated proteins CLDN5 and OCLN,
while transcription of TJP1 remained almost unaffected. Of note,
LTAextract was consistently more efficacious in attenuating the
expression of CLDN5 and OCLN than LTApure, which is at variance
with the activity of LPSultrapure to elevate the expression of CLDN5
mRNA. Although we do not know whether these changes in mRNA
expression translate to changes in actual BBB integrity and func-
tion, it is emerging from other studies that the effect of TLR2 and
TLR4 agonists on tight junction-associated protein mRNA expres-
sion in the brain is related to neuroinflammation and its deleteri-
ous impact on the BBB. In vitro studies have revealed that TNF-a,
IL-1b, and IL-6 (all being elevated in the present study) increase
Fig. 7. Effect of LTApure, LTAextract, and LPSultrapure on tight junction-associated protein mRNA expression in the amygdala (A, C, E) and prefrontal cortex (B, D, F). The graphs
depict the expression of claudin 5 (CLDN5; A, B), occludin (OCLN; C, D), and tight junction protein 1 (TJP1; E, F) mRNA. LTApure (20 mg/kg), LTAextract (20 mg/kg), LPSultrapure
(1938 EU/kg  0.19 mg/kg) or the respective vehicle (VEH) was administered 3 h before the tight junction-associated proteins were assayed. mRNA transcription is expressed
as fold change relative to VEH-treated mice. The bars represent means + SEM, n = 5–7; *p 6 0.05, **p 6 0.01, ***p 6 0.001 compared to VEH-treated mice, independent samples
t test.
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et al., 1996). It is obvious from these findings that cytokines can
induce aberrant BBB function, an activity that could be exploited
to increase delivery of pharmaceuticals to the brain (Wardill
et al., 2016). CCL2 (also elevated in the present study), which is a
critical mediator of inflammation within and outside the central
nervous system (Bennett et al., 2003), can disrupt BBB function
via C-C chemokine receptor type 2-mediated signaling pathways
that lead to myosin light chain hyperphosphorylation (Yao and
Tsirka, 2014).
Further work has shown that highly purified LTA from S. aureus
concentration- and time-dependently influences BBB integrity via
activation of glial cells in a co-culture model of bovine brain capil-lary endothelial cells and rat primary glial cells (Boveri et al., 2006).
One report holds that nitric oxide, TNF-a, and IL-1b produced by
activated glial cells affect the BBB (Boveri et al., 2006), while
another report suggests that the main BBB offenders are TNF-a,
IL-1b, and IL-6 (De Vries et al., 1996). While Boveri et al. (2006)
failed to observe a significant change in CLDN and OCLN expression
following treatment with highly purified LTA from S. aureus in an
in vitro BBB model, Singh et al. (2007) found a decrease of OCLN
mRNA after LTA (purity not specified) treatment of endothelial
cells. In spite of these inconsistencies it has been shown that LTA
is crucial for S. aureus to adhere to and invade brain endothelial
cells via surface anchoring (Sheen et al., 2010). The current finding
of a pronounced decrease in CLDN5 and OCLN mRNA expression in
R. Mayerhofer et al. / Brain, Behavior, and Immunity 60 (2017) 174–187 185the amygdala and prefrontal cortex, along with an increase in
pro-inflammatory cytokine expression, supports the contention
that TLR2-mediated neuroinflammation is closely related to a
disruption of the molecular BBB composition. It should not go
unnoticed that the effect of LTA on tight junctions is region-
dependent, given that LTA from E. hirae has been shown to amelio-
rate TLR2-mediated intestinal epithelial tight junction impairment
(Miyauchi et al., 2008).
4.3. Effect of LTA on HPA axis activity and anxiety-like behavior
Induction of neuroinflammatory processes in the brain by TLR4
agonists such as LPS is known to induce a syndrome of behavioral
changes known as sickness response, followed by an increase in
anxiety- and depression-like behavior (Bluthé et al., 1994;
Dantzer, 2004). Although TLR2 agonism also causes immune acti-
vation in the brain and attenuates the expression of BBB compo-
nents as shown here, there is scarce information on any
behavioral alterations due to LTA-induced TLR2 agonism. TLR2
appears to play a role in the anxiety-like behavior of a murine
schizophrenia model, given that anxiety-like behavior in the open
field and elevated plus maze test is reduced in TLR2 knockout mice
(Park et al., 2015). In addition, cytokines are thought to participate
in the etiology of anxiety disorders (Vogelzangs et al., 2016). The
present study, however, indicates that the molecular changes
induced by LTApure in the brain do not translate to any behavioral
changes in the open field test. In contrast, LTAextract was able to
enhance anxiety-like behavior, an effect that is likely due to the
LPS contamination, as LPSultrapure likewise had an anxiogenic
action. Importantly, the doses of LTApure, LTAextract and LPSultrapure
examined in this study were too low to induce overt sickness
behavior, which would be reflected by a decrease of the traveling
distance in the open field (Painsipp et al., 2010).
Activation of the HPA axis by internal and external stressors is
known to have an impact on emotional-affective behavior includ-
ing anxiety (Jacobson, 2014). As shown here, the plasma concen-
tration of corticosterone was enhanced by LTApure, LTAextract and
LPSultrapure as measured 3 h post-injection. Stimulation of murine
PRRs such as TLR4 by LPS has previously been found to activate
the HPA axis and cause the release of corticosterone (Farzi et al.,
2015b; Lehmann et al., 2013), and a similar observation has been
made with LTA (species and purity not specified) at a dose of
1 mg/kg (Bergt et al., 2013). Our finding indicates that stimulation
of the HPA axis by systemic LTA does not result in short-term
changes of anxiety-like behavior. It awaits to be investigated, how-
ever, whether the profound molecular changes induced by TLR2
agonism in the brain manifest themselves in long-term alterations
of brain function and yet-to-be-identified behavioral traits.
5. Conclusions
Our work has shown that the effects of LTA on immune-brain
communication depend to a good deal on the source and purity of
the LTA preparation under study. This limitation can be overcome
by the use of a highly purified LTA preparation, biologic validation
of its selectivity as a TLR2 agonist and careful analysis of the effects
that potential LPS/endotoxin contaminations may contribute.
Through this approach we have been able to disclose that selective
stimulation of TLR2 by purified LTA not only causes peripheral
immune activation but also initiates neuroinflammatory processes
in the brain as mirrored by transcriptional up-regulation of pro-
inflammatory cytokines. These neuroinflammatory processes take
place in parallel with a transcriptional down-regulation of tight
junction-associated proteins, which points to a deleterious effect
on themolecular composition of the BBB. In contextwith other stud-
ies we conclude that TNF-a and IL-6 may be major regulators of thetransition from peripheral immune stimulation to neuroinflamma-
tion and disruption of the BBB. The molecular changes evoked by
TLR2 activation extend to activation of the HPA axis but have little
impact on emotional behavior, unless TLR2 is concomitantly acti-
vated with TLR4, which appears to boost peripheral and cerebral
immune activation and to enhance anxiety. In a translational per-
spective, the joint effect of different PRR agonists is of pathophysio-
logic relevance under conditions of bacterial invasion or
translocation when different PRRs are activated in parallel. Con-
stituents of the vast intestinal microbiota will also cause immune
activation if the intestinal mucosal barrier is disrupted and allows
for translocation of microbial constituents (Garrett et al., 2010;
Inman et al., 2012; Kelly et al., 2015; Maslanik et al., 2012). There
is increasing evidence that a disturbed interaction between the gut
microbiota and the intestinal immune system has an impact on
mental health (Kelly et al., 2015; Sampson and Mazmanian, 2015).
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